Clinic and pathogenesis of severe bullous skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis

Drug Hypersensitivity

Volumn , Issue , 2007, Pages 267-277

  Allanore, Laurence ^a   Roujeau Prof , Jean Claude ^a  

^a HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67349107933     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000104206     Document Type: Chapter

References (26)

1. Lyell A: Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68: 355-361.
2. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC: Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138: 1019-1024.
3. Cote B, Wechsler J, Bastuji-Garin S, Assier H, Revuz J, Roujeau JC: Clinicopathologic correlations in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 1995; 131: 1268-1272.
4. Aurelian L, Ono F, Burnett J: Herpes simplex virus-associated erythema multiforme: a viral disease with an autoimmune component. Dermatol Online Journal 2003; 9: 1.
5. Cheriyan S, Patterson R, Greenberger PA, Grammer LC, Latall J: The outcome of Stevens-Johnson syndrome treated with corticosteroids. Allergy Proc 1995;16: 151-155.
6. Arroyo MP, Sanders S, Yee H, Schwartz D, Kamino H, Strober BE: Toxic epidermal necrolysis-like reaction secondary to colchicine overdose. Br J Dermatol 2004; 150: 581-588.
7. Orion E, Matz H, Wolf R: The lifethreatening complications of dermatologic therapies. Clin Dermatol 2005; 23: 182-192.
8. Nassif A, Bensussan A, Boumsell L, Deniaud A, Moslehi H, Wolkenstein P, Bagot M, Roujeau JC: Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J Allergy Clin Immunol 2004; 114: 1209-1215.
9. Pichler WJ: Delayed drug hypersensitivity reactions. Ann Intern Med 2003; 139: 683-693.
10. Yawalkar N, Hari Y, Frutig K, Egli F, Wendland T, Braathen LR, Pichler WJ: T cells isolated from positive epicutaneous test reactions to amoxicillin and ceftriaxone are drug specific and cytotoxic. Invest Dermatol 2000; 115: 647-652.
11. Viard I, Wehrli P, Bullani R, Schneider P, Holler N, Salomon D, Hunziker T, Saurat JH, Tschopp J, French LE: Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282: 490-493.
12. Paquet P, Pierard GE: Keratinocyte injury in toxic epidermal necrolysis: simultaneous but distinct topographic expression of CD95R and calprotectin. Int J Mol Med 2002; 10: 145-147.
13. Billingham RE, Streilein JW: Toxic epidermal necrolysis and homologous disease in hamsters. Arch Dermatol 1968; 98: 528-539.
14. Azukizawa H, Kosaka H, Sano S, Heath WR, Takahashi I, Gao XH, Sumikawa Y, Okabe M, Yoshikawa K, Itami S: Induction of T-cell-mediated skin disease specific for antigen transgenically expressed in keratinocytes. Eur J Immunol 2003; 33: 1879-1888.
15. Azukizawa H, Sano S, Kosaka H, Sumikawa Y, Itami S: Prevention of toxic epidermal necrolysis by regulatory T cells. Eur J Immunol 2005; 35: 1722-1730.
16. Roujeau JC, Bracq C, Huyn NT, Chaussalet E, Raffin C, Duedari N: HLA phenotypes and bullous cutaneous reactions to drugs. Tissue Antigens 1986;28: 251-254.
17. Lonjou C, Thomas L, Borot N, Ledger N, de Toma C, LeLouet H, Graf E, Schumacher M, Hovnanian A, Mockenhaupt M, Roujeau JC; RegiSCAR Group: A marker for Stevens-Johnson syndrome...: ethnicity matters. Pharmacogenomics J 2006; 6: 265-268.
18. Wolkenstein P, Carriere V, Charue D, Bastuji-Garin S, Revuz J, Roujeau JC, Beaune P, Bagot M: A slow acetylation genotype is a risk factor for sulphonamide-induced toxic epidermal necrolysis and Stevens-Johnson syndrome. Pharmacogenetics 1995; 5: 255-258.
19. Dietrich A, Kawakubo Y, Rzany B, Mockenhaupt M, Simon JC, Schopf E: Low N-acetylating capacity in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Exp Dermatol 1995; 4: 313-316.
20. Hein DW, Doll MA, Fretland AJ, Leff MA, Webb SJ, Xiao GH, Devanaboyina US, Nangju NA, Feng Y: Molecular genetics and epidemiology of the NAT1 and NAT2 acetylation polymorphisms. Cancer Epidemiol Biomarkers Prev 2000; 9:29-42.
21. Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P: SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-153.
22. Wysowski DK, Swartz L: Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002. Arch Intern Med 2005; 165: 1363-1369.
23. Garcia-Doval I, LeCleach L, Bocquet H, Otero XL, Roujeau JC: Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323-327.
24. Wolkenstein P, Latarjet J, Roujeau JC, Duguet C, Boudeau S, Vaillant L, Maignan M, Schuhmacher MH, Milpied B, Pilorget A, Bocquet H, Brun-Buisson C, Revuz J: Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-1589.
25. Faye O, Roujeau JC: Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. Drugs 2005; 65: 2085-2090.
26. Roujeau JC, Stern RS: Severe adverse cutaneous reactions to drugs. N Engl J Med 1994; 331: 1272-1285.